BDBM304095 (R)-2-(1-((4-Carboxyphenyl)amino)-3-cyclobutyl-1-oxopropan-2-yl)-5-(3-chloro-6-(difluoromethyl)-2-fluorophenyl)pyridine 1-oxide::US10143681, Example 4
SMILES: OC(=O)c1ccc(NC(=O)[C@H](CC2CCC2)c2ccc(c[n+]2[O-])-c2c(F)c(Cl)ccc2C(F)F)cc1
InChI Key: InChIKey=QELFRIHVHVRUFC-LJQANCHMSA-N
Data: 2 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasma kallikrein (Homo sapiens (Human)) | BDBM304095 ((R)-2-(1-((4-Carboxyphenyl)amino)-3-cyclobutyl-1-o...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Sharp & Dohme Corp. US Patent | Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a... | US Patent US10143681 (2018) BindingDB Entry DOI: 10.7270/Q2348NG3 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Coagulation factor XI (Homo sapiens (Human)) | BDBM304095 ((R)-2-(1-((4-Carboxyphenyl)amino)-3-cyclobutyl-1-o...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.360 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Sharp & Dohme Corp. US Patent | Assay Description The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine... | US Patent US10143681 (2018) BindingDB Entry DOI: 10.7270/Q2348NG3 | |||||||||||
More data for this Ligand-Target Pair |